iBio, Inc.IBIONYSE
Loading
Cash Flow Under PressureContracting
Percentile Rank20
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-19.19M
↑ 16% vs avg
Percentile
P20
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
$-22.86M
Historical baseline
PeriodValueYoY Change
TTM$-19.19M-25.3%
2025$-15.32M+18.4%
2024$-18.76M+48.1%
2023$-36.17M+19.8%
2022$-45.13M-28.1%
2021$-35.23M-143.0%
2020$-14.50M+3.1%
2019$-14.96M-2.8%
2018$-14.56M+1.3%
2017$-14.76M-